THEOPHYLLINE- theophylline tablet, extended release

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

THEOPHYLLINE ANHYDROUS (UNII: 0I55128JYK) (THEOPHYLLINE ANHYDROUS - UNII:0I55128JYK)

Available from:

Camber Pharmaceuticals, Inc.

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline extended-release tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Product summary:

Theophylline Extended-release Tablets: 300 mg: White to off- white colored, capsule shaped, bevel edged, biconvex tablets, debossed with ‘T’ and score line on one side and ‘V’ on the other side.     Bottle of 100   NDC 31722-077-01 450 mg: White to off- white colored, capsule shaped, bevel edged, biconvex tablets, debossed with ‘T’ and ‘1’ separated by a score line on one side and ‘V’ on the other side.    Bottle of 100    NDC 31722-078-01     Dispense in a well-closed container, with child resistant closure [as defined in the USP].   Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].  Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Annora Pharma Pvt. Ltd. Sangareddy - 502313, Telangana, India.            Revised: 08/2023

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

THEOPHYLLINE - THEOPHYLLINE TABLET, EXTENDED RELEASE
CAMBER PHARMACEUTICALS, INC.
----------
THEOPHYLLINE EXTENDED-RELEASE TABLETS
RX ONLY
DESCRIPTION:
Theophylline is structurally classified as a methylxanthine. It occurs
as a crystalline
powder, white, practically odourless. Theophylline anhydrous USP has
the chemical
name 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione and is represented
by the following
structural formula:
C
H
N
O
M.W.
180.17.
This product allows a 12-hour dosing interval for a majority of
patients and a 24-hour
dosing interval for selected patients (see DOSAGE AND
ADMINISTRATIONsection for
description of appropriate patient populations).
Each extended-release tablet for oral administration contains either
300 mg or 450 mg
of theophylline anhydrous USP. Tablets also contain as inactive
ingredients:
hypromellose, lactose monohydrate, magnesium stearate and povidone.
CLINICAL PHARMACOLOGY:
MECHANISM OF ACTION:
Theophylline has two distinct actions in the airways of patients with
reversible
obstruction; smooth muscle relaxation (i.e., bronchodilation) and
suppression of the
response of the airways to stimuli (i.e., non-bronchodilator
prophylactic effects). While
the mechanisms of action of theophylline are not known with certainty,
studies in
animals suggest that bronchodilation is mediated by the inhibition of
two isozymes of
phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while
non-bronchodilator
prophylactic actions are probably mediated through one or more
different molecular
mechanisms, that do not involve inhibition of PDE III or antagonism of
adenosine
receptors. Some of the adverse effects associated with theophylline
appear to be
mediated by inhibition of PDE III (e.g., hypotension, tachycardia,
headache, and emesis)
and adenosine receptor antagonism (e.g., alterations in cerebral blood
flow).
Theophylline increases the force of contraction of diaphragmatic
muscles. This action
appears to be due to enhancement of calcium uptake through an
adenosine-mediated
channel.
SERUM CONCE